A Long-Term Safety Trial of Treatment With Nebulized SUN-101 in Patients With COPD
Status:
Completed
Trial end date:
2016-02-01
Target enrollment:
Participant gender:
Summary
This is a long-term safety trial of 48 weeks. Eligible subjects will enter the 48-week,
open-label treatment period to receive one of two treatments (SUN-101 given as 50 mcg twice a
day or Spiriva® [tiotropium] given as 18 mcg once a day).